1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Drugs In Development, 2022, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 40, 13, 2, 31 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 4 and 1 molecules, respectively.
Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Ewing Sarcoma - Overview
- Ewing Sarcoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Ewing Sarcoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Ewing Sarcoma - Companies Involved in Therapeutics Development
- Ewing Sarcoma - Drug Profiles
- Ewing Sarcoma - Dormant Projects
- Ewing Sarcoma - Discontinued Products
- Ewing Sarcoma - Product Development Milestones
- Featured News & Press Releases
- Sep 28, 2022: Rakovina Therapeutics announces upcoming scientific conference presentations
- May 11, 2022: Rakovina Therapeutics presents preclinical data on its novel kt-3000 series at the 2022 AACR Special Conference on Sarcomas
- Apr 23, 2022: Nektar and collaborators present preclinical data on NKTR-255, a novel IL-15 receptor agonist, in combination with CAR cell therapies at the 2022 Tandem Meetings - Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
- Mar 30, 2022: Rakovina Therapeutics to present abstract at the 2022 AACR special conference - Sarcomas
- Nov 01, 2021: Inhibrx announces participation in upcoming scientific and investor conferences
- May 10, 2021: TYME announces abstract selected for publication at the 2021 American Society of Clinical Oncology Annual Meeting
- Aug 24, 2020: New treatment developed by CHOP shows success in high-risk solid tumors
- Aug 11, 2020: TYME announces outcome of interim futility review for HopES sarcoma phase II study
- May 28, 2020: TYME announces abstracts selected for publication at the 2020 American Society of Clinical Oncology Annual Meeting
- May 14, 2020: Cellectar granted composition of matter and use patent in Europe for CLR 131
- Jan 16, 2020: TYME and The Joseph Ahmed Foundation announce first patient dosed in phase II (HopES) trial evaluating the potential benefits of oral SM-88 for patients with high-risk sarcomas
- Aug 20, 2019: NanoValent Pharmaceuticals announces issuance of United States patent for application of targeted polymerized nanoparticles in cancer treatment
- Aug 14, 2019: CLR 131 advances to second malignant brain tumor cohort of ongoing pediatric phase 1 study
- May 23, 2019: TYME and The Joseph Ahmed Foundation announce initiation of the HopES Phase II trial evaluating the potential benefits of SM-88 for patients with high-risk Sarcomas
- Mar 04, 2019: Gradalis announces medical leadership team promotion
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Ewing Sarcoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Ewing Sarcoma - Dormant Projects, 2022
- Ewing Sarcoma - Discontinued Products, 2022
- Number of Products under Development for Ewing Sarcoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A2A Pharmaceuticals Inc
- Aadi Bioscience Inc
- Actuate Therapeutics Inc
- ADC Therapeutics SA
- Advenchen Laboratories LLC
- AI Therapeutics Inc
- Altay Therapeutics Inc
- Amgen Inc
- AntiCancer Inc
- APEIRON Biologics AG
- Aptadel Therapeutics SL
- Atlanthera
- Aurora BioPharma Inc
- Bayer AG
- BioAtla Inc
- BioMarck Pharmaceuticals Ltd
- Bristol-Myers Squibb Co
- CancerVAX Inc
- Cebiotex SL
- Celldex Therapeutics Inc
- Cellectar Biosciences Inc
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chimerix Inc
- Cornerstone Pharmaceuticals Inc
- Cothera Bioscience Pty Ltd
- Diatheva srl
- Edison Oncology Holding Corp
- Eisai Co Ltd
- Eli Lilly and Co
- ENB Therapeutics LLC
- EntreChem SL
- Esperas Pharma Inc
- Exelixis Inc
- Fusion Pharmaceuticals Inc
- Gate2Brain SL
- GenFleet Therapeutics (Shanghai) Inc
- Gibson Oncology LLC
- Gradalis Inc
- GSK plc
- Hutchison MediPharma Ltd
- ImmunityBio Inc
- Inhibrx Inc
- Ipsen SA
- Iterion Therapeutics Inc
- JSK Therapeutics Inc
- Lantern Pharma Inc
- MacroGenics Inc
- Mana Therapeutics Inc
- MediaPharma SRL
- Merck & Co Inc
- NanoValent Pharmaceuticals Inc
- Natsar Pharmaceuticals Inc
- Nektar Therapeutics
- Novartis AG
- Ohara Pharmaceutical Co Ltd
- Oncology Pharma Inc
- Oncomatryx Biopharma SL
- OncoTartis Inc
- Orgenesis Inc
- Orphelia Pharma SAS
- Peel Therapeutics Inc
- Pfizer Inc
- Pharma Mar SA
- Prelude Therapeutics Inc
- Provectus Biopharmaceuticals Inc
- QSAM Therapeutics Inc
- Rakovina Therapeutics Inc
- Salarius Pharmaceuticals Inc
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Shionogi & Co Ltd
- Sorrento Therapeutics Inc
- Syros Pharmaceuticals Inc
- Tarveda Therapeutics Inc
- Theranano LLC
- Tyme Inc
